Transplantation of CD34+selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution
| Autor: | E Monteagudo, Joaquín Martínez, Ignacio Lorenzo, Guillermo Sanz, G Martín, C Jiménez, M J Remigia, Federico Moscardó, Isidro Jarque, Miguel A. Sanz, Susana Cantero, J de la Rubia, Pau Montesinos |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
medicine.medical_specialty Transplantation Conditioning Allogeneic transplantation Adolescent CD3 Complex Cyclophosphamide aplastic anemia Premedication Graft vs Host Disease Antigens CD34 Gastroenterology Prednisone Internal medicine medicine Humans Transplantation Homologous Aplastic anemia Child CD34+selection Preparative Regimen Peripheral Blood Stem Cell Transplantation Transplantation business.industry Histocompatibility Testing Siblings Graft Survival Bone marrow failure Anemia Aplastic Hematology Middle Aged medicine.disease peripheral blood Surgery allogeneic transplantation Survival Rate Kinetics Treatment Outcome Absolute neutrophil count Radiotherapy Adjuvant business medicine.drug |
| Zdroj: | BONE MARROW TRANSPLANTATION r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 0268-3369 |
| Popis: | We evaluated the use of CD34+ selected allogeneic peripheral blood as a source of hematopoietic progenitors for allogeneic transplantation in 11 patients with aplastic anemia ( AA). The median age was 17 years ( range, 6 - 49), and the median time between diagnosis and transplant 1 month ( range, 1 - 24). Conditioning consisted of cyclophosphamide ( 50 mg/ kg per day) on days -7 to -4 and antithymocyte globulin ( 30 mg/ kg per day) on days -4 to -2 in nine patients. Total lymphoid irradiation was added to the preparative regimen for two. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and prednisone. Median doses of CD34+ and CD3+ cells infused were 3.91 x 10(6) and 0.3 x 10(6)/kg, respectively. The median time taken to achieve a neutrophil count > 0.5 x 10(9)/l was 12 days and to recover a platelet count > 20 x 10(9)/l, 13 days. Two patients developed acute GVHD grade I-II and one developed limited chronic GVHD. There were two treatment-related deaths. At a median follow-up of 44 months ( range, 4 - 73), nine patients were alive with sustained and complete engraftment. This is a promising procedure in patients with AA, resulting in a rapid hematopoietic recovery, a low transplant-related mortality, and a low incidence of GVHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|